Conclusions
INFLUENZA
In summary, this study demonstrated high user acceptability with the web-based survey platform compared to that with a mobile app. Making AEFI reporting available to existing mobile app users may still be a viable initiative for participant-centered active reporting in Canada but would require further refinement.We wish to thank the individuals who participated in this study. This project was supported by The Ottawa Hospital Academic Medical Organization (TOHAMO) and The Ottawa Hospital Foundation. The Canadian National Vaccine Safety Network as part of the Canadian Immunization Research Network is funded by a research grant from the Canadian Institutes of Health Research and the Public Health Agency of Canada (grant #151944; June 1, 2017, to December 31, 2022).Conflicts of Interest: KW, KA, and CB were cofounders and shareholders of CANImmunize Inc, a corporation that provides consumer facing solutions to immunization information systems. KW has served on the Medicago Independent Data Monitoring Committee and is a member of the Moderna Global Safety Core Consultancy Group. All other authors have no conflicts of interest to disclose.
This randomized study was only registered retrospectively due to delays caused by the COVID-19 pandemic. The editor granted an exception from ICMJE rules mandating prospective registration of randomized trials, because the risk of bias appears low. However, readers are advised to carefully assess the validity of any potential explicit or implicit claims related to primary outcomes or effectiveness, as retrospective registration does not prevent authors from changing their outcome measures retrospectively.Useability survey responses for new compared to previous users of the influenza vaccine safety survey web platform.CONSORT-eHEALTH checklist (V 1.6.1).